Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04705818
Other study ID # IB2019-04
Secondary ID 2019-003303-35
Status Recruiting
Phase Phase 2
First received
Last updated
Start date July 23, 2021
Est. completion date January 2025

Study information

Verified date February 2023
Source Institut Bergonié
Contact Antoine ITALIANO, MD,PhD
Phone (0)5.56.33.33.33
Email a.italiano@bordeaux.unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Umbrella study structure to independently and simultaneously assess the effects of the association of durvalumab and tazemetostat in multiple solid tumors.


Description:

4 independant, multicenter, prospective, signle-arm phase II trials, based on 2-stage Simon's optimal design, will be conducted in parallel to assess the efficacy of durvalumab when prescribed with tazemetostat, separately, in distinct cohorts of solid tumors: - cohort A: patients with pancreatic cancer - cohort B: patients with colorectal cancer not MSI-H or MMR-deficient - cohort C: patients with metastatic solid tumors with positive interferon gamma signature and/or tertiary lymphoid structure positive - cohort D: patients with soft-tissue sarcoma


Recruitment information / eligibility

Status Recruiting
Enrollment 173
Est. completion date January 2025
Est. primary completion date July 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Histology: histologically confirmed solid tumors including pancreatic cancer (cohort A), non MSI-H or MMR-deficient colorectal cancer (cohort B), solid tumor with positive IFNG gene expression signature and/or tertiary lymphoid structure positive (cohort C), soft-tissue sarcomas (Cohort D). Other solid tumor types may be included through future amendment of the current version of the study protocol. Note: for cohort C, IFNG gene expression and/or presence of tertiary lymphoid structure will be centrally assessed. Cohort D, diagnosis must be confirmed and reviewed by the RRePS Network.as recommended by the French NCI (Inca). 2. For cohort C, availability of archived FFPE tumor tissue sample for IFNG gene expression assessment and/or determination of the presence of tertiary lymphoid structure, 3. Advanced disease defined as metastatic or unresectable locally advanced disease, 4. Age = 18 years, 5. ECOG, Performance status = 1, 6. Measurable disease according to RECIST 7. Life expectancy > 3 months, 8. Participant must have advanced disease and must not be a candidate for other approved therapeutic regimen known to provide significant clinical benefit based on investigator judgment, 9. Adequate hematological, renal, metabolic and hepatic functions 10. No prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma, 11. At least three weeks since last chemotherapy, immunotherapy or any other pharmacological treatment and/or radiotherapy, 12. Recovery to grade = 1 from any adverse event (AE) derived from previous treatment, excluding alopecia of any grade and non-painful peripheral neuropathy grade = 2 13. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to inclusion. 14. Both women and men must agree to use a highly effective method of contraception throughout the treatment period and for at least nine months after discontinuation of treatment for women and six months after discontinuation of treatment for men. 15. Voluntary signed and dated written informed consents prior to any specific study procedure, 16. Participants with a social security in compliance with the French law. Exclusion Criteria: 1. Previous treatment with durvalumab or tazemetostat, 2. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA-4 antibody, 3. EGFR/ALK/ROS mutated NSCLC, 4. Evidence of progressive or symptomatic central nervous system or leptomeningeal metastases, 5. Participation to a study involving a medical or therapeutic intervention in the last 30 days, 6. Previous enrolment in the present study, 7. Participant unable to follow and comply with the study procedures because of any geographical, familial, social or psychological reasons, 8. Known hypersensitivity to any involved study drug or of its formulation components, 9. Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent 10. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to the first dose of trial treatment, 11. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan or interstitial lung disease with ongoing signs and symptoms at inclusion. History of radiation pneumonitis in the radiation field (fibrosis) is permitted, 12. Has known active tuberculosis, hepatitis B or hepatitis C, 13. Has a known history of Human Immunodeficiency Virus or known acquired immunodeficiency syndrome, 14. Persistent proteinuria > 3.5 g/24 hours measured by urine protein-creatinine ratio from a random urine sample (= Grade 3, NCI-CTCAE v5), 15. Major surgical procedure or significant traumatic injury within 28 days before inclusion, 16. Non-healing wound, non-healing ulcer, or non-healing bone fracture, 17. Participants with evidence or history of any bleeding diathesis, irrespective of severity, 18. Any hemorrhage or bleeding event = CTCAE Grade 3 within 4 weeks prior to inclusion, 19. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before inclusion (except for adequately treated catheter-related venous thrombosis occurring more than one month before inclusion), 20. Ongoing infection > Grade 2 as per NCI CTCAE v5, 21. Uncontrolled hypertension (Systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg) despite optimal medical management, 22. Congestive heart failure = New York Heart Association class 2, 23. Unstable angina, new-onset angina (begun within the last 3 months), 24. Myocardial infarction less than 6 months before inclusion, 25. Uncontrolled cardiac arrhythmias, 26. Pregnant or breast-feeding participants, 27. Individuals deprived of liberty or placed under legal guardianship, 28. Prior organ transplantation, including allogeneic stem cell transplantation, 29. Known alcohol or drug abuse, 30. Participants with any condition that impairs their ability to swallow and retain tablets, 31. Other severe acute or chronic medical conditions including immune inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study, 32. Participant with anti-Vitamine K oral anticoagulation therapy, 33. Suspected or known intraabdominal fistula, 34. Screening QTc interval > 480 msec is excluded, 35. Has received a live vaccine within 30 days prior to the first dose of trial treatment. 36. Participants with a prior history of myeloid malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or myeloproliferative neoplasm (MPN), 37. Participants with a prior history of T-cell lymphoblastic lymphoma (T-LBL) / T-cell lymphoblastic leukemia (T-ALL).

Study Design


Intervention

Drug:
Durvalumab
Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)
Tazemetostat
Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).

Locations

Country Name City State
France Institut Bergonie Bordeaux
France CHRU Brest Brest
France CHU Poitiers Poitiers

Sponsors (3)

Lead Sponsor Collaborator
Institut Bergonié AstraZeneca, Epizyme, Inc.

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort A Antitumor activity will be assessed in terms of disease control rate, defined as complete response (CR), partial response (PR) and stable disease (SD) as per RECIST v1.1 criteria Within 6 months of treatment onset
Primary Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort B Antitumor activity will be assessed in terms of disease control rate, defined as CR, PR and SD as per RECIST v1.1 criteria Within 6 months of treatment onset
Primary Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort C Antitumor activity will be assessed in terms of objective response rate, defined as CR and PR as per RECIST v1.1 criteria Within 6 months of treatment onset
Primary Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort D Antitumor activity will be assessed in terms of 6-months progression-free rate, defined as CR, PR and SD as per RECIST v1.1 criteria 6 months
Secondary Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort D Antitumor activity will be assessed in terms of objective response rate, defined as CR and PR as per RECIST v1.1 criteria Within 6 months of treatment onset
Secondary Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort A Antitumor activity will be assessed in terms of 6-months progression-free rate, defined as CR, PR and SD as per RECIST v1.1 criteria 6 months
Secondary Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort B Antitumor activity will be assessed in terms of 6-months progression-free rate, defined as CR, PR and SD as per RECIST v1.1 criteria 6 months
Secondary Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort C Antitumor activity will be assessed in terms of 6-months progression-free rate, defined as CR, PR and SD as per RECIST v1.1 criteria 6 months
Secondary 6-month objective response (OR) independently for each population Objective response is defined as the proportion of patients with complete response (CR) or partial response (PR) observed at 6 months, based on RECIST 1.1 criteria 6 months
Secondary Best overall response, independently for each population Best overall response is defined as the best response across all time points (RECIST 1.1). The best overall response is determinded once all the data for the patient is known (RECIST 1.1) Throughout the treatment period, an expected average of 6 months
Secondary 1-year progression-free survival, independently for each population Progression-free survival is defined as the delay between the start date of treatment and the date of progression (as per RECIST 1.1) or death (from any cause), whichever occurs first 1 year
Secondary 1-year overall survival, independently for each population Overall survival is defined as the delay between the start date of treatment and the date of death (of any cause) 1 year
Secondary Safety profile, independently for each population: Common Terminology Criteria for adverse events version 5 Toxicity graded using the Common Terminology Criteria for Adverse Events vers 5 Throughout the treatment period, an expected average of 6 months
Secondary Tumor immune cell levels Levels of immune cells in tumors will be measured by immunohistochemistry before treatment onset, cycle 2 day 1 and cycle 3 day 1 (each cycle is 21 days)
Secondary Blood cytokines level Levels of cytokines in blood will be measured by ELISA before treatment onset, cycle 2 day 1, cycle 3 day 1 and treatment discontinuation (each cycle is 21 days)
Secondary Blood lymphocytes level Levels of lymphocytes in blood will be measured by flow cytometry before treatment onset, cycle 2 day 1, cycle 3 day 1 and treatment discontinuation (each cycle is 21 days)
Secondary Blood kynurenin level Levels of kynurenin in blood will be measured by ELISA before treatment onset, cycle 2 day 1, cycle 3 day 1 and treatment discontinuation (each cycle is 21 days)
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT05508100 - Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors Phase 1
Not yet recruiting NCT05515185 - B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors Early Phase 1
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT02836600 - A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04890613 - Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1/Phase 2
Recruiting NCT06007482 - A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Completed NCT04108676 - Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects Phase 1
Recruiting NCT05798611 - Study of ART0380 in Patients With Biologically Selected Solid Tumors Phase 2
Recruiting NCT05076396 - PM14 Administered Intravenously to Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06008366 - A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06054932 - Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors Phase 1
Recruiting NCT04825392 - A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06365918 - Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis Phase 1
Recruiting NCT05569057 - A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma Phase 1
Recruiting NCT05443126 - A Study of EP0031 in Patients With Advanced RET-altered Malignancies Phase 1/Phase 2
Recruiting NCT05461287 - Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors Phase 1